最近对冠状动脉附带循环的最新见解
1Second Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.
Circulation
|March 1, 1992
概括
冠状动脉附带体通过减少心脏病发作的大小和改善功能,在心肌梗塞期间保护心脏. 氨酸可能会增强缺血性心脏病的治疗性血管生成.
科学领域:
- 心脏病学 心脏病学
- 血管生物学 血管生物学
- 再生医学是一种再生医学.
背景情况:
- 长期以来,人们一直在讨论冠状动脉附带因素在人类心脏病中的作用.
- 附带血管对于为缺血性心脏组织提供血液至关重要.
- 了解附带的发展和功能是治疗心脏病的关键.
研究的目的:
- 为了研究冠状动脉附带因素在心肌梗塞中的功能意义.
- 探索抵押品发展的机制和增长因素的作用.
- 评估肝素在促进冠状动脉疾病血管生成方面的治疗潜力.
主要方法:
- 关联急性心肌梗塞期间的附带可视化与临床结果 (心脏梗塞大小,心室功能).
- 检查细胞和分子机制的附带生长,以应对缺血.
- 临床试验评估肝素与冠状动脉疾病患者的运动结合的疗效.
主要成果:
- 视觉化冠状动脉附带体与较小的心脏病发作,较少的动脉瘤形成和更好的心室功能有关.
- 心肌缺血刺激了通过DNA复制和细胞分裂的附带发育.
- 氨酸增强生长因子,促进血管生成,改善患者的运动能力.
结论:
- 冠状动脉附带体在缺血性心脏病中起着重要的保护作用.
- 血管新生由生长因子刺激,并可能被肝素强化,提供了一种治疗策略.
- 对新血管化的进一步研究可能会导致缺血性心脏病的新疗法.
相关概念视频
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation I: Introduction
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


